The primary objective of this randomised, placebocontrolled, double-blind, crossover study, was to evaluate and compare the longer term effects of the angiotensin II type 1 receptor antagonist losartan and the converting enzyme inhibitor enalapril on 24-h ambulatory blood pressure ( 
Introduction
Interference with the renin-angiotensin-aldosterone system is one of several modalities to lower blood pressure (BP) in patients with hypertension. Inhibitors of the angiotensin converting enzyme (ACE) partially counteract the formation of angiotensin II whereas the more recently developed nonpeptide orally active angiotensin II receptor antagonists block the octapeptide's binding to the type 1 receptor. Most of the cardiovascular effects of angiotensin II in adults, such as vasoconstriction, stimulation of aldosterone release and cellular growth, are attributable to the angiotensine II type 1 receptor. When hypertensive patients were allocated at random to treatment with the ACE inhibitor enalapril, or with the angiotensin II receptor antagonist losartan, the two approaches led to similar clinic BP reductions at trough, [1] [2] [3] [4] though enalapril appeared to be more effective at peak. 1, 2 Ambulatory BP was, however, not monitored to compare the diurnal profile of the two drugs. In addition, such parallel studies cannot answer the question whether the response to the two drug classes would be similar in the individual patient. We have previously demonstrated a tight correlation between BP changes when hypertensive patients were consecutively treated with the peptide angiotensin II antagonist saralasin and the ACE inhibitor captopril; 5 on average, the captoprilinduced BP change was more pronounced than the response to saralasin, which could either be attributed to additional antihypertensive actions of captopril or to the agonistic effect of saralasin, or to both. This issue of the relative potency of angiotensin II antagonists vs ACE inhibitors in the same patient is particularly relevant when side effects develop to one of the drugs, in which case the physician may want to switch to a drug from the other class. It has also been argued that more complete blockade of the renin-angiotensin system by combination of both drug classes might lower BP to a greater extent. [6] [7] [8] The primary aim of the present study was to compare, using a randomised, placebo-controlled, double-blind, crossover design, the effects of 6-week treatment with losartan and enalapril on ambulatory and conventional BP in patients with essential hypertension. A secondary aim was to repeat ambulatory BP monitoring after 1 month of open combined therapy in patients with insufficient BP control on monotherapy.
Materials and methods

Patients
White patients with essential hypertension, aged у18 years, in World Health Organization stages I or II, were eligible for the study. Patients with any disease that could interfere with the study protocol were excluded, as were women when pregnant or receiving oral contraceptives. The protocol was approved by the Ethics Committee of the Faculty of Medicine of the KU Leuven and participants gave written witnessed informed consent to participate in the study.
Treatment protocol
Eligible patients were invited for an initial visit after they had not been administered antihypertensive treatment for at least 2 weeks. They entered a 4-week run-in period during which they received two placebo capsules each day. Patients were instructed to ingest the study medication in the morning with their breakfast, between 07.00 and 08.00, including on visit days; they were asked to keep general lifestyle, diet and physical activity constant. Patients who satisfied the BP criteria on the final day of placebo treatment (mean sitting diastolic BP у95 mm Hg and р105 mm Hg) were allocated randomly to be administered either placebo, the converting enzyme inhibitor enalapril (20 mg o.d.) or the angiotensin II receptor antagonist losartan (50 mg o.d.). However, the placebo period was always scheduled between the two active treatment periods, which was not known to the investigators who performed the measurements. Each treatment period lasted 6 weeks. Capsules containing placebo, enalapril or losartan had the same shape and colour.
At the end of the double-blind study, patients whose clinic BP remained higher than 130/85 mm Hg 9 in all double-blind periods, were proposed to be treated with the combination of enalapril 20 mg and losartan 50 mg per day for the next 4 weeks.
Clinical measurements
A clinical examination including assessment of body height was performed initially. Blood pressure, heart rate and body weight were measured at each clinic visit. All visits during the double-blind period were scheduled in the morning in the laboratory. Conventional BP was measured by the same investigator using a mercury sphygmomanometer (Korotkoff phase V for diastolic BP), three times in the supine position and three times in the sitting position, after 15 and 5 min rest, respectively; the three pressures were averaged for later analysis. Pulse rate was determined during 30 s in each position.
Ambulatory BP monitoring
Ambulatory BP monitoring was performed during the 24 hours preceding the clinic visit, using the Spacelabs 90207 device (Redmond, Washington, USA). The BP was measured every 15 min from 08.00 to 22.00 and every 30 min between 22.00 and 08.00. The ambulatory BP recordings were not edited, that is, readings were only excluded if they had not been completed successfully by the monitor or if they fell outside the preset boundaries for BP and heart rate (systolic BP Ͻ70 or Ͼ260 mm Hg, diastolic BP Ͻ40 or Ͼ150 mm Hg, pulse pressure Ͻ20 or Ͼ150 mm Hg, heart rate Ͻ20 or Ͼ200 beats/min). The following average BPs were derived: the average 24-h BP, daytime BP or the average BP between 10.00 and 20.00, and night time BP as the pressure between 24.00 and 06.00. Patients were asked to go to bed between 20.00 and 24.00, and to get up between 06.00 and 10.00. In these conditions the narrow clock-time dependent daytime and night time pressures have been shown to be similar to the actual awake and asleep pressures.
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Biochemical measurements
Routine biochemical variables, including blood glucose and serum creatinine, sodium and potassium concentrations, were determined on venous blood, as were plasma renin activity 11 and circulating ACE.
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Statistical analysis
Database management and statistical analyses were performed using SAS software (SAS Institute Inc., Cary, North Carolina, USA). Group data are reported as means ± standard deviation (s.d.). Positively skewed data were transformed logarithmically for the statistical analyses. The effects of treatment were assessed by use of repeated measures analysis of variance. For the double-blind study, we compared the data obtained with placebo, enalapril and losartan; the data during combined therapy were compared to those on monotherapy with, respectively, enalapril and losartan. Relationships between treatment-induced changes were analysed using single regression analysis. Two-tailed P р 0.05 was considered statistically significant.
Results
Patients
Twelve patients entered the run-in period. One patient dropped out during this period and two others were excluded because their sitting diastolic BP was Ͼ105 mm Hg on placebo. Nine men with essential hypertension entered the double-blind phase of the study. Age averaged 46 ± 6 years and body mass index 26.9 ± 2.2 kg/m 2 . Median duration of hypertension was 6 months (range 1 to 120). Five patients had previously been treated for hypertension, two were current smokers. Mean supine and sitting BPs at the end of the run-in period averaged 160 ± 17/94 ± 8 mm Hg, and 154 ± 13/102 ± 3 mm Hg, respectively. Corresponding heart rates were 70 ± 18 and 75 ± 17 beats/min. Daytime, night time and 24-h ambulatory BP averaged 156 ± 10/102 ± 10 mmHg, 132 ± 11/83 ± 9 mm Hg and 148 ± 10/96 ± 9 mm Hg, respectively. Serum creatinine averaged 94 ± 12 mol/L and urinary sodium excretion 165 ± 67 mmol/24 h.
All patients completed the double-blind protocol. Of seven patients who started combined treatment, one interrupted the therapy because of cough, which he also experienced when taking enalapril alone. The age of the six remaining patients averaged 45 ± 5 years. Baseline sitting BP was 152 ± 15/103 ± 3 mm Hg and 24-h ambulatory pressure 150 ± 12/97 ± 10 mm Hg. Values are means ± s.d. *P р 0.05; **P р 0.01; ***P р 0.005 for the comparison of active treatment with placebo. a P value for the comparison of losartan (L) and enalapril (E).
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Ambulatory and conventional BP Table 1 summarises the results on BP. The systolic and diastolic daytime, night time and 24-h ambulatory blood pressures during the double-blind placebo period were similar to those during the baseline investigations (0.48 р P р 0.97). Both enalapril and losartan reduced ambulatory BP. When the results of the two drugs were directly compared, enalapril was more effective than losartan with regard to BP during the day (P = 0.03 for systolic and P = 0.01 for diastolic pressure) but not for BP during the night (P у 0.46). Heart rate was not influenced by either drug except for a slightly lower night time heart rate during enalapril than during placebo treatment (P Ͻ 0.05). Figure 1 illustrates the hourly means of systolic and diastolic BP for the three treatment modalities, starting at 07.00 in the morning, showing roughly similar BPs during enalapril and losartan treatment, except from about 11.00 to 19.00, corresponding to the significant difference in daytime pressure (Table 1 ). Both drugs decreased clinic BP compared to placebo. The losartan-induced BP changes were close to and not significantly different from those obtained with enalapril (0.17 р P р 0.47). Heart rate was not influenced by any drug in any position.
Relationships between treatment-induced changes in BP
The correlation coefficients of the relationships between the enalapril-and losartan-induced changes in systolic and diastolic BP were between 0.63 and 0.90 for the daytime, night time and 24-h ambulatory pressures and between 0.77 and 0.93 for Figure 1 Hourly means of ambulatory systolic and diastolic BP (mm Hg) during placebo, losartan and enalapril treatment. See Table 1 for statistical analysis on daytime, night time and 24-h pressure.
the supine and sitting conventional pressures. Figure 2 illustrates the results for the systolic 24-h ambulatory pressure, for which the correlation coefficient amounted to 0.74 (P = 0.02). 
Biochemical data
Blood glucose and serum sodium, potassium and creatinine concentrations were not significantly different between placebo, enalapril and losartan treatment during the double-blind phase of the study, except for a slightly higher serum creatinine concentration on enalapril (97.5 ± 10.6 mol/L) than on placebo (93.7 ± 11.7 mol/L) (P = 0.06). Circulating ACE was similar during placebo (37 ± 13 U/L) and losartan treatment (38 ± 15 U/L) but was significantly (P Ͻ 0.001) lower on enalapril (11 ± 17 U/L). Log plasma renin activity averaged −0.137 ± 0.350 on placebo (antilog or geometric mean: 0.73 g/L/h) and increased significantly (P Ͻ 0.005) to +0.165 ± 0.510 on enalapril (antilog: 1.46 g/L/h) and to +0.090 ± 0.396 (antilog: 1.23 g/L/h) on losartan; the treatment-induced changes did not differ between the two active treatment regimens (P = 0.25).
Combined treatment
Six patients were investigated on combined treatment with enalapril and losartan, when 24-h ambulatory BP was significantly lower than on placebo (P р 0.01). Figure 3 gives hourly means for ambulatory BP during placebo, during combined treatment, and on monotherapy with, respectively, enalapril and losartan. Average daytime, night time and 24-h BPs on combined therapy were not significantly different from those on enalapril alone (0.17 р P р 0.78) ( Table 2 ). However, daytime but not night time BP was lower during combined treatment than on losartan alone; daytime BP averaged 148.5/96.5 mm Hg during losartan, and 139.5/89.7 mm Hg during combined treatment (P = 0.02 for systolic and P = 0.01 for diastolic pressure). With regard to renal function, serum creatinine increased from 94 ± 12 mol/L on placebo to 104 ± 11 mol/L on combined therapy (P = 0.05), which was, however, not significantly different from the level achieved during enalapril treatment (100 ± 6 mol/l).
Discussion
Previous randomised studies which compared the BP lowering effects of the angiotensin II type 1 receptor antagonist losartan and the converting enzyme inhibitor enalapril, were performed according to a multicentre, double-blind, parallel group design, following a placebo run-in period, and measured clinic BP at trough [1] [2] [3] [4] and in some also at peak. 1, 2 In the present single centre study, we used a randomised double-blind, placebo-controlled, crossover protocol at the end of a 4-week placebo baseline period. In such a design each patient serves as his own control, so that the response to the drugs can be compared in the individual patient, and inclusion of a placebo-period in the double-blind phase minimises the non-pharmacological effects on BP such as regression-to-the-mean and habituation Table 2 for statistical analysis on daytime, night time and 24-h pressure. Values are means ± s.d. a P value for the comparison of combined treatment (C) with, respectively, enalapril (E) and losartan (L).
to the measurement conditions. Furthermore, ambulatory BP was selected as the primary endpoint. This BP is devoid of the white coat effect and has been shown to be highly reproducible on repeated measurements over short periods of time, 13 which is confirmed in the present study by the almost identical ambulatory BP during the baseline investigations and the placebo period.
The main findings of the double-blind part of the present study are that: (1) losartan and enalapril reduce ambulatory BP throughout the 24-h period, (2) that enalapril and losartan lower BP to approximately the same extent, except for a more pronounced effect of enalapril on daytime ambulatory BP, and (3) that the losartan-induced pressure changes are significantly related to those obtained with enalapril.
Enalapril and losartan were administered once daily in the morning, during 6 weeks each, in doses
Journal of Human Hypertension that were given in most parallel group studies, ie 20 mg of enalapril and 50 mg of losartan, 1,2,4 and in agreement with these studies, drug doses were not titrated. Ambulatory monitoring revealed that this dose of losartan reduced 24-h BP by 9.4/7.2 mm Hg in comparison to placebo, which is similar to previous findings.
14 Furthermore, both losartan and enalapril decreased BP throughout the 24-h period, but enalapril caused a significantly greater BP reduction than losartan during the day, from approximately 11.00 to 19.00. The fact that clinic BP did not differ between the two drugs can be explained by the ambulatory BP profile, which shows that on-treatment BP was similar between 09.00 and 11.00, that is at the time when conventional BP was measured during the clinic visit. These results are in fact compatible with those from parallel group studies, in which the same drug doses were used as in our study. Indeed, losartan and enal-april caused similar reductions in BP at trough, ie approximately 24 h after drug intake, 1,2,4 which concords with our finding of no BP difference among drugs during the night and early morning. By contrast, the BP response to enalapril was significantly better than the response to losartan at peak, ie on average 6 1 or 8 2 hours after dosing, which is compatible with the lower ambulatory BP on enalapril during late morning and in the afternoon in the current study, in which drugs were taken between 07.00 and 08.00. We are not aware of other randomised, double-blind, crossover studies in patients with essential hypertension. Gansevoort et al 15 consecutively administered increasing doses of losartan and of enalapril to 11 such patients in a single-blind design, each treatment period lasting 1 month. Ontreatment clinic mean BP averaged 100 mm Hg on 50 mg of losartan and 93 mm Hg on 20 mg of enalapril but the significance of this difference was not reported.
Angiotensin II antagonists are proposed as an alternative to converting enzyme inhibitors in patients who experience cough on the latter drug class 9 but it is not known whether the two drug classes would lead to similar BP control in the same patient. We found significant relationships between the BP responses to losartan and to enalapril, consistent with the correlations between the pressure changes obtained with the peptide angiotensin II antagonist saralasin, and with the ACE inhibitor captopril (r = 0.88; P Ͻ 0.001). 5 It is unlikely that such associations are spurious findings because, for example, there was no relationship whatsoever between the BP response to the thiazide bendrofluazide and the beta-blocker atenolol in a previous double-blind crossover trial. 16 As previously observed, 17 both approaches to block the renin-angiotensin system produced an increase in plasma renin activity, presumably related to interruption of the negative feedback of angiotensin II on renin release. This may be particularly relevant for the angiotensin II antagonist because the ensuing elevation of circulating angiotensin II levels would stimulate the unblocked angiotensin II type 2 receptor, which acts as an antagonistic receptor against the angiotensin II type 1 receptor and mediates vasodilatation and antiproliferation. 18 It has even been shown in certain cell types that stimulation of the angiotensin II type 2 receptor triggers kinin generation and NO-production, suggesting kinin-mediated effects of angiotensin II antagonists. 19 However, the biological importance of these effects in human essential hypertension is still being debated. 20 A limitation of the current study is the small number of subjects. On the other hand, we applied the more powerful crossover design, studied a homogeneous group of middle-aged men with essential hypertension, included ambulatory BP monitoring, and all investigations were performed by the same investigators in a single centre. The considerable suppression of circulating ACE during enalapril treatment and the rise in plasma renin activity on both drugs, suggest good patient compliance with regard to drug intake. Furthermore the results are plausible in view of previous findings by use of other study designs. It can, however, not be excluded that different drug doses would have led to different conclusions. For example, Weber et al 14 observed that 24-h ambulatory BP was lower on losartan 50 mg twice daily than on losartan 50 mg once daily.
Combined treatment with enalapril and losartan was not included in the double-blind protocol of the present study, because of the possible occurrence of adverse hypotension. However, we took the opportunity to study the effects of combined treatment by inviting patients whose BP was not fully normalised 9 in any double-blind treatment period, to take both drugs during 1 more month. Because of the open nature of this part of the study only ambulatory BP was considered. We found no convincing evidence that adding losartan to enalapril would lead to a consistent and substantial further decrease of BP, which suggests that alternative angiotensin II formation during converting enzyme inhibition is not of particular relevance with regard to its hypotensive action. To the best of our knowledge, the effects of combined longer-term treatment of losartan 50 mg and enalapril 20 mg have not been reported previously. The combination of 50 mg of losartan and 10 mg of enalapril induced a somewhat larger decrease of BP than just 10 mg of enalapril in acute studies in 12 sodium depleted normotensive subjects. 7 Losartan 50 mg plus captopril 50 mg was also more powerful than captopril alone in similar experiments. 6 Fogari et al 8 observed that the combined administration of losartan 50 mg and lisinopril 10 mg during 4 weeks, produced a greater reduction in both ambulatory and casual BP compared with lisinopril 20 mg, in hypertensive patients whose condition was not controlled by lisinopril 10 mg once daily; however, the effect of adding losartan to the same dose of the converting enzyme inhibitor was not assessed. On the other hand, BP control during the day was better on combined treatment than on losartan alone in the present study, which suggests that mechanisms other than those related to blockade of the reninangiotensin system, such as bradykinin accumulation, 21 contribute to the BP lowering effect of converting enzyme inhibition. Finally, combined treatment led to a slight 10% increase in serum creatinine, which was, however, not different from the level achieved on enalapril alone, so that there was no evidence of a detrimental effect on renal function with more complete blockade of the reninangiotensin system than with ACE inhibition alone. It is obvious that these preliminary findings on combined treatment should be confirmed in properly designed prospective studies.
